NCT00026312 2026-03-05
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Completed
Clinical Trials
22 trialsNCT01175356 2026-01-23
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Children's Oncology Group
Phase 1 Completed
NCT03033303 2025-10-07
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02169609 2024-04-22
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Phase 2 Completed
NCT01526603 2024-02-26
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT00567567 2022-04-28
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT03291080 2021-10-19
My-CRA
Nova Laboratories Limited
Phase 1/2 Completed
NCT00499616 2021-07-06
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT02100930 2020-02-28
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01334515 2019-10-21
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Completed
NCT01183416 2019-10-09
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01183429 2019-08-13
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01208454 2015-11-24
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01592045 2015-09-23
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
United Therapeutics
Phase 1/2 Completed
NCT00217412 2014-06-17
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00070200 2014-02-13
Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma
Children's Oncology Group
Phase 1 Completed
NCT00004110 2013-10-31
Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00004188 2013-05-17
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT00040872 2013-03-07
Multiple Therapies in Treating Patients With Advanced Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00089258 2013-01-17
Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00005576 2013-01-16
Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00135135 2008-06-03
Therapy for Children With Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed